Increasing evidence shows that short-term insulin intensive therapy can alleviate glucose toxicity, lipotoxicity and IR, and improve islet β cell function in newly diagnosed type 2 diabetics, but the study about its effect in inhibiting the MCP-1 and NF-κB expression in diabetic patients in vivo has not been reported. The gene discussed is CCL2; the disease is type 2 diabetes mellitus.